KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 52-Week High Following Analyst Upgrade

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) reached a new 52-week high on Friday after Stifel Nicolaus raised their price target on the stock from $39.00 to $42.00. Stifel Nicolaus currently has a buy rating on the stock. KalVista Pharmaceuticals traded as high as $19.27 and last traded at $18.95, with a volume of 2400756 shares. The stock had previously closed at $17.14.

A number of other research analysts have also recently commented on the stock. Citizens Jmp dropped their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a report on Thursday. Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Needham & Company LLC upped their target price on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday. TD Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $32.60.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 6,693 shares of the company’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $16.08, for a total transaction of $107,623.44. Following the sale, the chief executive officer owned 451,815 shares of the company’s stock, valued at approximately $7,265,185.20. This represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Nicole Sweeny sold 3,975 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $61,890.75. Following the sale, the insider owned 47,003 shares of the company’s stock, valued at approximately $731,836.71. The trade was a 7.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 33,378 shares of company stock valued at $522,290. Insiders own 4.30% of the company’s stock.

Key Stories Impacting KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Company reported $49.1M in EKTERLY revenue during an eight‑month transition period and highlighted a strong launch that supports topline growth expectations. KalVista posts $49.1 million in EKTERLY revenue
• Positive Sentiment: Corporate update and eight‑month FY2025 results emphasized commercial progress and operational updates that underpin near‑term revenue visibility. KalVista Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and kept a “buy” rating — implying ~122% upside from the current price — reflecting bullish analyst views on commercial execution and upside potential. Stifel raises KALV price target
• Positive Sentiment: Needham & Company increased its target from $35 to $36 and maintained a “buy” rating, signaling continued analyst confidence in EKTERLY’s market opportunity. Needham raises KALV price target
• Neutral Sentiment: Q1/8‑month earnings call transcripts (and related highlights) are available; these provide detail on revenue cadence, channel dynamics, and management commentary that investors should review for execution risk and guidance clarity. Q1 2025 earnings call transcript 8 Months 2025 earnings call transcript
• Negative Sentiment: Citizens Jmp trimmed its price target from $29 to $28 and moved to “market outperform” — a mild downgrade in target that could temper enthusiasm despite still-significant upside (~48%). Citizens Jmp lowers KALV price target

Institutional Trading of KalVista Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Tudor Investment Corp ET AL bought a new stake in KalVista Pharmaceuticals in the third quarter valued at $24,360,000. Vestal Point Capital LP raised its stake in KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after buying an additional 1,140,000 shares during the period. Parkman Healthcare Partners LLC raised its stake in KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after buying an additional 1,055,940 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of KalVista Pharmaceuticals by 2,258.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after purchasing an additional 905,053 shares in the last quarter. Finally, Elmind Capital LP acquired a new position in KalVista Pharmaceuticals during the fourth quarter worth $12,941,000.

KalVista Pharmaceuticals Price Performance

The stock has a market capitalization of $957.92 million, a P/E ratio of -4.80 and a beta of -0.35. The business’s 50 day simple moving average is $15.95 and its two-hundred day simple moving average is $14.44. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.